• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Euthymics Bioscience, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Euthymics Bioscience, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 29 pages
  • Global Markets Direct

Euthymics Bioscience, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Euthymics Bioscience, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Euthymics Bioscience, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Euthymics Bioscience, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Euthymics Bioscience, Inc. Snapshot
Euthymics Bioscience, Inc. Overview
Key Information
Key Facts
Euthymics Bioscience, Inc. – Research and Development Overview
Key Therapeutic Areas
Euthymics Bioscience, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Euthymics Bioscience, Inc. – Pipeline Products Glance
Euthymics Bioscience, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Euthymics Bioscience, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Euthymics Bioscience, Inc. – Drug Profiles
DOV 216,303
Product Description
Mechanism of Action
R&D Progress
EB-1010
Product Description
Mechanism of Action
R&D Progress
DOV 102,677
Product Description
Mechanism of Action
R&D Progress
DOV 216,419
Product Description
Mechanism of Action
R&D Progress
Euthymics Bioscience, Inc. – Pipeline Analysis
Euthymics Bioscience, Inc. – Pipeline Products by Therapeutic Class
Euthymics Bioscience, Inc. Pipeline Products By Target
Euthymics Bioscience, Inc. – Pipeline Products by Route of Administration
Euthymics Bioscience, Inc. – Recent Pipeline Updates
Euthymics Bioscience, Inc. - Dormant Projects
Euthymics Bioscience, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Feb 29, 2008: DOV Pharmaceutical Initiates A Phase II Study Of DOV 21,947 In Patients With Major Depressive Disorder
Sep 05, 2007: DOV Pharmaceutical Announces Results From Additional Phase Ib Of DOV 21,947
Sep 05, 2007: DOV Pharmaceutical Announces Results From Additional Phase Ib Of DOV 21,947
Aug 09, 2007: DOV Pharmaceutical, Inc. Announces Results From Phase Ib Results Of DOV 21,947
Feb 24, 2005: DOV Initiates Phase I Trial Of DOV 102,677
Aug 05, 2004: DOV Pharmaceutical And Merck Announce Agreement To Develop And Commercialize Novel Depression Compounds
Aug 05, 2004: DOV Pharmaceutical And Merck Announces Agreement To Develop And Commercialize Novel Depression Compounds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS